We have conducted a retrospective study on 251 patients from three centers in France and Switzerland between 2004 and 2010 with the goal to evaluate the impact of HLA-DRB3/B4/B5 allele mismatching after HLA-10/10-matched unrelated allogeneic hematopoietic stem cell transplantation (HSCT). Fourteen (5.5%) patients receiving HSCT from an HLA-10/10-matched unrelated donor had a mismatched DRB4 donor, 23 (9.5%) patients had a mismatched DRB3 donor and 214 (85%) had a fully matched unrelated donor (HLA-10/10) without DRB3-or DRB4-mismatched donor. We compared the outcomes of 37 patients with a DRB3 or DRB4 mismatch with the rest of the population. The median survival for a patient without DRB3/4 mismatch was 18 months (95% confidence interval (CI), 13-29), for DRB3-mismatched patients 32 months (95% CI, 13-NR) and for DRB4-mismatched patients 7 months (95% CI, 3-NR). The multivariate analysis showed a significant impact of DRB4 mismatching on survival (Hazards ratio (HR) = 2.1 (95% CI, 1.01-4.67), P = 0.045), acute GvHD (HR = 2.66 (95% CI, 0.99-7.09) P = 0.05) and on transplant-related mortality (HR = 2.8; (95% CI, 1.7 − 4.4) P = 0.024). In the view of an impact of DRB4 locus mismatch on clinical outcome, it would be important to confirm this observation in a prospective study as it may be worth considering DRB4 in the unrelated donor selection.
INTRODUCTION
Patients with hematologic diseases who need an allogeneic hematopoietic stem cell transplantation (HSCT) as treatment and do not have an HLA-identical sibling donor can now be successfully transplanted with an HLA-matched unrelated donor. However, these patients are at a higher risk for post-transplantation complications such as acute GvHD (aGvHD) and chronic GvHD (cGvHD) and transplant-related mortality (TRM). [1] [2] [3] Recent technological advances allow performance of high-resolution typing by molecular methods allowing precise recipient/donor HLA-matching assessment. High-resolution matching is carried out for HLA-A, -B, -C and -DRB1 loci because an adverse effect on survival is well documented in the presence of a single mismatch for one of these loci. Clinical studies have demonstrated that HLA allelic disparities correlate with an increased risk of graft failure, aGvHD and mortality. [4] [5] [6] On the basis of numerous studies, the minimum standard of 'fully matched' unrelated donor is an allele matched for HLA-A, -B, -C and -DRB1 (8/8-HLA matched) unrelated donor. 7 Currently, in most transplant centers, HLA-DRB3/4/5 loci are not taken into account for the choice of unrelated donor because their significance is less clear. In this setting, a few recent studies concluded to the necessity of studying DRB3/4/5 incompatibilities in large retrospective and prospective studies without interference of incompatibilities at the HLA-A,-B,-C,-DRB1 and -DQB1 loci. 8, 9 In this report, we reviewed the collaborative experience of three HLA transplant centers and their laboratories for histocompatibility in France (Lyon and Lille) and Switzerland (Geneva) with the aim to evaluate the impact of HLA DRB3, DRB4 and DRB5 allele mismatching after HLA-10/10-matched unrelated allogeneic HSCT.
MATERIALS AND METHODS

Patients and transplantation
We conducted a retrospective study on 251 consecutive patients who received an allogeneic HSCT for malignant disease from an HLA-10/10-matched unrelated donor between 2004 and 2010. There were 134 (53%) male and 117 (47%) female patients in the cohort. The diagnosis was acute myeloblastic leukemia for 88 (35%) patients, ALL for 29 (11.5%), myelodysplastic/myeloproliferative syndromes for 55 (22%), multiple myeloma for 32 (12.5%) and 47 patients (19%) had CML, CLL, Hodgkin's lymphoma and non-Hodgkin's lymphoma. One hundred and twenty patients (48%) received myeloablative conditioning and 131 patients (52%) received reduced intensity conditioning. At transplantation, 140 patients (58%) were in CR, 111 (42%) were in o CR; 121 (48%) patients received PBSC transplantation and 130 (52%) bone marrow. All data are summarized in Table 1 .
HLA typing and matching
The unrelated donors from international registries were typed at high resolution for HLA-A,-B,-C,-DRB1 and -DQB1 alleles by bi-allelic sequencebased typing (Abbott Laboratories, Abbott Park, IL, USA). Residual ambiguities located in exons 2 and 3 for class I and in exon 2 for class II were resolved by additional PCR-SSO (One Lambda, Canoga Park, CA, USA) or allelic PCR-SSP (Olerup, Vienna, Austria). DRB3/4/5 typing was performed using PCR-SSP (Olerup, Vienna, Austria).
Clinical data and end points
The principal objective was to determine the incidence of aGvHD, cGvHD, PFS, overall survival and TRM between patients with an HLA-10/10-matched unrelated donor without DRB3/4/5 mismatch and patients with an HLA-10/10-matched unrelated donor with a DRB3-or DRB4-associated mismatch.
The clinical data (aGvHD, relapse, survival, cGvHD, date of last visit and alive/dead status) were available for all patients who are eligible for inclusion and collected by participating transplant centers. All data were collected according to the institutional review board-approved guidelines and protocols of each participating institution. Informed consent for clinical research was obtained at the time of transplantation for each recipient according to the Declaration of Helsinki for participation.
Primary outcomes analyzed were overall survival, PFS, relapse of malignancy, aGvHD and cGvHD. aGvHD was classified as clinically significant (grades 2-4) or severe (grades 3-4). aGvHD grades were defined by the Glucksberg scale. 10 cGvHD was classified as limited or extensive. cGvHD was defined by Seattle criteria. 11 
Statistical analysis
Overall survival was calculated from the date of transplantation until the date of death, PFS was defined as survival from transplantation to the first event (disease progression or death). Relapse was defined as a recurrence of the underlying hematological malignant disease in cytological examination of marrow or in a computer tomographic scanner following hematological pathology. TRM was defined as death during continuous remission.
The Kaplan-Meier method was used to estimate the overall survival, PFS and TRM. Comparison tests among the different groups were realized by the log-rank test. The Cox proportional hazard regression model was used for multivariate analysis on survival, aGvHD and cGvHD and the Fine and Gray for TRM, PFS and relapse as competing risks. 12 In these models the DRB3, DRB4 or DRB5 mismatch was adjusted with the following covariates: age, kind of disease, sexmatching, ABO matching, CMV status of donor and patient, TBI in conditioning, antithymocyte globulins (ATG), disease status at transplantation, type of conditioning regimen and stem cell source. Center effect was previously tested and was not present.
RESULTS
Patients
In this cohort, 14 (5.5%) patients receiving HSCT from an HLA-10/10-matched unrelated donor had a mismatched DRB4 donor, 23 (9.5%) patients had a mismatched DRB3 donor and 214 (85%) had a HLA-10/10-matched unrelated donor without any DRB3 or DRB4 mismatch. We did not find any pair with a mismatch at DRB5 locus.
The median age was 52 years (range, 19-70) and the median follow-up of the study was 60 months (range, 3-70). There were no significant differences between the three groups regarding gender, disease, disease stage, stem cell source, age and conditioning regimen intensity. The outcome of the 37 patients with a DRB3 or DRB4 mismatch was compared with the remaining population.
Regarding HLA typing, most of the DRB3-mismatched pairs included a DRB1*13:01 allele (17/23) and 47% of those (8/17) had a common haplotype: A*02:01, B*15:01, C*03:03, DRB1*13:01, DQB1*06:03, (DPB1*04:01). All DRB3 mismatches included the DRB3*01:01 and DRB3*02:02 alleles whatever the DRB1 alleles. Most of the DRB4-mismatched pairs were positive for the DRB1*07:01 allele (11/14) but no recurrent haplotype was identified. DRB4 mismatches included DRB4*01:03, *01:03 N, *01:01, *01:02 and *03:01 N alleles. DPB1 typing was available for all pairs, with 5.4% (2/37) being DPB1 identical, 59.4% (22/37) semi-identical and 35.2% (13/37) mismatched for the two DPB1 alleles.
Among our 37 mismatched pairs for DRB3 and DRB4, we identified 2 pairs with a DRB3 mismatch in GvHD direction, 3 pairs with a DRB3 or DRB4 mismatch in host-versus-graft direction and 32 pairs with a mismatch in both directions. The small number of patients did not allow statistical testing of these data.
Engraftment and GvHD
After a median follow-up of 60 months (range, 3-70), 241 patients (96%) had engrafted. Among 243 evaluated patients for aGvHD at Day +90, 67 (27.5%) patients developed aGvHD with a grade ⩾ 2. Extensive cGvHD developed in 45 (21%) patients among 212 Abbreviations: AML = acute myeloblastic leukemia; BM = bone marrow; CML = chronic myeloblastic leukemia; F = female; HL = Hodgkin's lymphoma; M = male; MAC = myeloablative regimen; MDS = myelodysplastic syndromes; MM = mismatch; MPS = myeloproliferative syndromes; NHL = non-Hodgkin's lymphoma; p/d = patient/donor; RIC = reduce intensity regimen.
Impact of HLA-DRB4 on outcomes after allogeneic HSCT M Detrait et al evaluated patients for cGvHD. The cumulative incidence of aGvHD ⩾ 2 at 3 months was 15% (95% confidence interval (CI),13-18) and the cumulative incidence of cGvHD at 1 year was 13% (95% CI, 10.5-16).
Overal survival, PFS and TRM The median survival for patient without DRB3,4,5 mismatch was 18 months (95% CI, 13-29), for DRB3-mismatched patients 32 months (95% CI, 13-NR) and for DRB4-mismatched patients 7 months (95% CI, 3-NR).
The probability of survival at 24 months without a DRB3/DRB4 mismatch was 40% (95% CI, 31-51), with a DRB3 mismatch 51% (95% CI, 12-33) and with a DRB4 mismatch 24% (95% CI, 9-64).
In this cohort of patients, 62 (25%) patients experienced relapse. The PFS and the TRM incidence at 24 months without DRB3/DRB4 mismatch was 34% (95% CI, 25-44) and 22% (95% CI,19.5-25), respectively, with DRB3 mismatch 49 (95% CI, 30-78) and 13% (95% CI, 6-20), respectively, and with DRB4 mismatch 25 (95% CI, 9-65) and 50% (95% CI, 35.5-64.5). The data are summarized in Table 2 .
Univariate and multivariate analysis In univariate analysis, a DRB3 mismatch had no impact on outcome, whereas DRB4 mismatch had a negative impact on TRM (P = 0.04) and a trend on aGvHD (P = 0.085). The multivariate analysis confirmed the univariate analysis with no impact of the DRB3 mismatching on survival, GvHD, PFS and TRM but a significant impact of DRB4 mismatching on survival (HR = 2.1 (95% CI, 1.01-4.67), P = 0.045, Figure 1 ), on aGvHD (HR = 2.66 (95% CI, 0.99-7.09) P = 0.05) and on TRM (HR = 2.8; (95% CI, 1.7 − 4.4) P = 0.024, Figure 2) . No impact on cGvHD, relapse and PFS for DRB3/4 mismatch was found in this cohort. Concerning DPB1 typing, in the group of 214 patients with HLA-10/10-matched patient/donor pairs we found that 183 patients (85.4%) were mismatched for DPB1 and in the group of 14 patients with an HLA-DRB4-mismatched donor, all patients were mismatched for DPB1. All data for multivariate analysis are described in Table 3 .
DISCUSSION
The primary objective of this study was to analyze the impact of HLA-DRB3, -DRB4 and -DRB5 allele mismatching on transplantation outcomes after HLA-10/10-matched unrelated allogeneic HSCT. Two hundred and fifty-one patients with HLA-10/10 (A-B-C-DRB1 and -DQB1)-matched donors were considered: 14 patients had a donor with DRB4 mismatch and 23 patients had a donor with a DRB3 mismatch. We found a small but significant impact of DRB4 mismatching on TRM and survival. To the best of our knowledge this is the first observation of a negative impact of DRB4 mismatches in the unrelated HLA-10/10-matched HLA donor transplantation setting. We cannot exclude the possibility that the DRB4 mismatching effect might be due to concomitant DPB1 mismatching. Concerning DRB3 mismatching, no negative impact on transplant outcome was disclosed, as shown in a previous study from the Swiss group.
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DRB4 mismatches have so far not been investigated in large cohorts, with the exception of a National Marrow Donor Program (NMDP) study by Fernandez-Vina et al. 13 reporting no impact of DRB3/4/5 mismatches in HLA-8/8-matched transplants. In this retrospective study on 1837 patients, there were 96 patients with a HLA-8/8 (A-B-C-DRB1)-matched donor who had a DRB3 mismatch, no patient with an HLA-8/8 donor had a DRB5 Table 2 . The Probability of overall survival, PFS and transplant-related mortality at 24 months after transplantation for the three groups of patients The comparison with our study is difficult because the level of HLA matching is different (HLA 8/8 vs 10/10) in the design at the beginning of the study and a scoring system was used in the NMDP study for mismatches in the low expression loci. We did not study the impact of associated mismatches such as DQA1, DPA1 and of course DQB1 because all our pairs were matched for the DQB1 locus. There are several limitations in our study to take into account: the patient sample is small, the retrospective model, the DPB1 matching and the HLA-9/10 donor selection were not considered; for these reasons, the results should be interpreted carefully. In an other way, the strength of this study rests in the collaborative experience of three transplant centers in France and Switzerland who share very similar practice in donor selection and patient treatment.
In the future, it will be important to confirm the possible impact of DRB4 incompatibilities on transplant outcome in a multicenter prospective study. We have now initiated a prospective evaluation of matching for DRB3/4/5 and DPB1 loci in the French cohort of Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) in the HLA-10/10 and -9/10 donor selection setting. Abbreviations: AML = acute myeloblastic leukemia; aGvHD = acute GvHD; CI = confidence interval; cGvHD = chronic GvHD; Do = donor; F = female; M = male; MDS = myelodysplastic syndromes; MM = mismatch; MPS = myeloproliferative syndromes; NHL = non-Hodgkin's lymphoma; OS = overall survival; PD = progressive disease; Re = recipient; TRM = transplant related mortality.
Impact of HLA-DRB4 on outcomes after allogeneic HSCT M Detrait et al
